These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34148469)

  • 1. How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation.
    Kotalczyk A; Potpara TS; Lip GYH
    Expert Opin Pharmacother; 2021 Oct; 22(14):1807-1810. PubMed ID: 34148469
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Stroke prevention in atrial fibrillation.
    Voukalis C; Shantsila E; Lip GY
    J R Coll Physicians Edinb; 2017 Mar; 47(1):13-23. PubMed ID: 28569277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants.
    Caturano A; Galiero R; Pafundi PC
    Medicina (Kaunas); 2019 Sep; 55(10):. PubMed ID: 31547188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischemic stroke in patients with atrial fibrillation receiving oral anticoagulation.
    Pujol Lereis VA; Ameriso S; Povedano GP; Ameriso SF
    J Neurol Sci; 2013 Nov; 334(1-2):139-42. PubMed ID: 24054537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Function in Atrial Fibrillation: A Multifaceted Dilemma.
    Hijazi Z; Wallentin L
    Circulation; 2016 Jul; 134(1):48-51. PubMed ID: 27358436
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 8. Starting anticoagulation with vitamin k antagonists alone or with concomitant low-molecular weight heparin for non-valvular atrial fibrillation.
    Sarrate E; Gual-Capllonch F; Sorigue M
    Eur J Intern Med; 2019 Jan; 59():e14-e15. PubMed ID: 30274903
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke.
    Diener HC; Ntaios G; O'Donnell M; Easton JD
    Expert Opin Pharmacother; 2018 Oct; 19(14):1597-1602. PubMed ID: 30152249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.
    Haft JI
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):241-8. PubMed ID: 22952215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant therapy in atrial fibrillation: vitamin K antagonists or novel oral anticoagulant drugs?
    Riva N; Borg Xuereb C; Ageno W
    J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):139-41. PubMed ID: 25539157
    [No Abstract]   [Full Text] [Related]  

  • 12. Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists.
    Gieling E; de Vries F; Williams R; van Onzenoort HAW; de Boer A; Ten Cate V; Kramers C; Burden A
    Int J Clin Pharm; 2019 Dec; 41(6):1536-1544. PubMed ID: 31595448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in very elderly patients with atrial fibrillation: a single-center experience.
    Weronska A; Broniatowska E; Papuga-Szela E; Undas A
    Kardiol Pol; 2020 Feb; 78(2):154-157. PubMed ID: 32108756
    [No Abstract]   [Full Text] [Related]  

  • 14. Stroke prevention in atrial fibrillation.
    Freedman B; Potpara TS; Lip GY
    Lancet; 2016 Aug; 388(10046):806-17. PubMed ID: 27560276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral anticoagulation in chronic kidney disease].
    Barrelet I; Mavrakanas T; Carballo S
    Rev Med Suisse; 2021 Jan; 17(722):142-145. PubMed ID: 33470571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants.
    Massaro A; Giugliano RP; Norrving B; Oto A; Veltkamp R
    Int J Stroke; 2016 Dec; 11(9):950-967. PubMed ID: 27703066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Stroke prevention in patients with atrial fibrillation].
    Sirimarco G; Hirt L; Sztajzel R; Perren F
    Rev Med Suisse; 2017 Apr; 13(560):911-915. PubMed ID: 28727359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why the four non-vitamin K-antagonist oral anticoagulants are actually five.
    Rubboli A
    Eur J Intern Med; 2020 Aug; 78():152-153. PubMed ID: 32312618
    [No Abstract]   [Full Text] [Related]  

  • 20. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Zirlik A; Bode C
    J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.